for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Biotest AG

BIOG_p.DE

Latest Trade

21.70EUR

Change

-0.65(-2.91%)

Volume

11,357

Today's Range

21.70

 - 

22.25

52 Week Range

19.82

 - 

25.00

As of on the XETRA ∙ Minimum 15 minute delay

Pricing

Previous Close
22.35
Open
21.90
Volume
11,357
3M AVG Volume
0.01
Today's High
22.25
Today's Low
21.70
52 Week High
25.00
52 Week Low
19.82
Shares Out (MIL)
39.57
Market Cap (MIL)
881.45
Forward P/E
-52.86
Dividend (Yield %)
--

Latest Developments

More

Biotest H1 Group EBIT At EUR -5.5 Mln

Biotest Q1 Loss After Tax From Continuing Operations At EUR -1.2 Mln

Biotest FY EAT From Continuing And Discontinued Operations At EUR 181.7 Mln

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Biotest AG

Biotest AG is a Germany-based provider of plasma proteins and biological drugs. The Company, with a chain that extends from pre-clinical and clinical development to worldwide marketing and distribution, mainly specializes in the areas of clinical immunology, hematology and intensive care medicine. Biotest AG develops, manufactures and markets immunoglobulin, coagulation factors and albumins based on human blood plasma. These are used for diseases of the immune and hematopoietic systems. In addition, the Company develops monoclonal antibodies in the indications of cancer of plasma cells and systemic lupus erythematosus, which are produced by recombinant technologies.

Industry

Biotechnology & Drugs

Contact Info

Landsteinerstr. 5

+49.6103.8010

https://www.biotest.com/

Executive Leadership

Rolf K. Hoffman

Chairman of the Supervisory Board

Michael Ramroth

Chairman of the Management Board, Chief Executive Officer

Cathrin Schleussner

Deputy Chairperson of the Supervisory Board

Martin Moeller

Group Finance and Treasury Officer

Georg Floss

Chief Operating Officer, Member of the Management Board

Key Stats

1.00 mean rating - 1 analysts
Sell
Hold
Buy
Price To Earnings (TTM)
--
Price To Sales (TTM)
2.23
Price To Book (MRQ)
1.77
Price To Cash Flow (TTM)
119.44
Total Debt To Equity (MRQ)
71.50
LT Debt To Equity (MRQ)
10.54
Return on Investment (TTM)
-0.36
Return on Equity (TTM)
-0.24

Latest News

BRIEF-Biotest FY Revenue Falls To EUR 378.1 Mln On Recall Of Human Albumin

* DGAP-ADHOC: BIOTEST AG: BIOTEST REACHES FY 2017 EBIT GUIDANCE

BRIEF-Biotest says Tiancheng to enter into domination agreement

* DGAP-ADHOC: BIOTEST AG: TIANCHENG INTENDS TO ENTER INTO A DOMINATION AND PROFIT AND LOSS TRANSFER AGREEMENT WITH BIOTEST AG

BRIEF-Biotest: Creat Takeover Of Biotest Closed

* MAJORITY SHAREHOLDING (APPROX. 90% OF BIOTEST'S ORDINARY SHARES AND VOTING SHARE CAPITAL) OF CREAT IN BIOTEST Source text for Eikon: Further company coverage: (Gdynia Newsroom)

Biotest sheds U.S. business to allay U.S. concerns of Chinese takeover

Biotest <BIOG.DE> said on Friday that it has sold its U.S. operations, allaying national security concerns by U.S. authorities and paving the way for the German company's sale to a Chinese investor.

BRIEF-Biotest: All Conditions Met For Creat Takeover Of Biotest

* DGAP-ADHOC: BIOTEST AG: ALL CONDITIONS MET FOR CREAT TAKEOVER OF BIOTEST

BRIEF-Biotest: Trimodulin Concept For Phase III Study Coordinated With The Authorities

* DGAP-NEWS: BIOTEST AG: TRIMODULIN: CONCEPT FOR PHASE III STUDY SUCCESSFULLY COORDINATED WITH THE AUTHORITIES Source text for Eikon: Further company coverage: (Gdynia Newsroom)

BRIEF-Biotest 9-mth revenue at EUR 377.8 mln

* DGAP-NEWS: BIOTEST AG: BIOTEST GENERATES REVENUES OF EUR 377.8 MILLION IN THE FIRST NINE MONTHS 2017

UPDATE 1-Takeover of plasma firm Biotest by China's Creat hits wall in U.S.

* Biotest shares drop 12 percent to 7-month low (Adds share price, background)

China's Creat suffers setback in Biotest deal on U.S. scrutiny

Chinese investor Creat Group Corp has withdrawn its application for U.S. approval of a planned 1.3-billion-euro ($1.51-billion) takeover of Biotest <BIOG_p.DE>, the German blood plasma products maker said, sending its shares sharply lower.

BRIEF-Biotest: Tiancheng withdrawal of application of transaction from CFIUS and refiling

* TENDER OFFER BY TIANCHENG (GERMANY) PHARMACEUTICAL HOLDINGS AG

BRIEF-Curetis partners with Biotest to support academic PEPPER Pentaglobin Peritonitis trial

* CURETIS PARTNERS WITH BIOTEST TO SUPPORT ACADEMIC PEPPER PENTAGLOBIN® PERITONITIS TRIAL WITH UNYVERO IAI APPLICATION

BRIEF-Biotest H1 result swings to loss of 17.8 million euros

* H1 REVENUE FROM CONTINUING OPERATIONS FELL 11 PERCENT TO 247.1 MILLION EUR

BRIEF-Biotest takes over plasma supplier Cara Plasma s.r.o.

* BIOTEST TAKES OVER CARA PLASMA S.R.O. WITH ONE PLASMA COLLECTION CENTRE IN CZECH REPUBLIC Source text for Eikon: Further company coverage: (Gdynia Newsroom)

BRIEF-Tiancheng Pharmaceutical Holdings: offer for Biotest accepted for 89.9 pct of share capital

* TIANCHENG (GERMANY) PHARMACEUTICAL HOLDINGS AG - AFTER END OF ADDITIONAL ACCEPTANCE PERIOD OFFER ACCEPTED FOR 17.8 MILLION BIOTEST SHARES, THAT IS 89.9% SHARE CAPITAL Source text for Eikon: Further company coverage: (Gdynia Newsroom)

BRIEF-Biotest reaches 2nd milestone in expansion project

* DGAP-NEWS: BIOTEST AG: BIOTEST REACHES 2ND MILESTONE IN BIOTEST NEXT LEVEL EXPANSION PROJECT

BRIEF-Tiancheng Pharmaceutical Holdings: additional acceptance period for Biotest tender offer

* START OF MANDATORY ADDITIONAL ACCEPTANCE PERIOD FOR BIOTEST AG TENDER OFFER Source text for Eikon: Further company coverage: (Gdynia Newsroom)

BRIEF-Tiancheng Pharmaceutical Holdings says Kreissparkasse Biberach tenders 15.17 pct stake in Biotest

* TIANCHENG PHARMACEUTICAL HOLDINGS AG - KREISSPARKASSE BIBERACH TENDERS 15.17% STAKE IN BIOTEST AG INTO TIANCHENG (GERMANY) PHARMACEUTICAL HOLDINGS AG'S TENDER OFFER Source text for Eikon: Further company coverage: (Gdynia Newsroom)

BRIEF-Tsinghua Tongfang aims to indirectly own stake in Germany's Biotest

* Says it plans to invest 2.05 billion yuan ($301.78 million) in Tiancheng International Investment Ltd, which plans to acquire stake in Germany's Biotest AG

BRIEF-Biotest ‍sells US therapy business to Adma Biologics, Inc.​

* RECEIVES ALSO DISTRIBUTION RIGHTS OF SPECIFIED CURRENT PRODUCT AND A RIGHT OF FIRST OFFER FOR DISTRIBUTION OF FUTURE PRODUCTS OF ADMA FOR EUROPE, NEAR AND MIDDLE EAST AND SELECTED ASIAN COUNTRIES

BRIEF-Biotest says board recommends to accept tender offer of Creat Group

* JOINT REASONED STATEMENT OF BIOTEST AG - MANAGEMENT BOARD AND SUPERVISORY BOARD RECOMMEND TO ACCEPT TENDER OFFER OF CREAT GROUP

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up